A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984
Open Access
- 1 July 2009
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (7) , 1292-1299
- https://doi.org/10.1038/mt.2009.80
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Biological Response Determinants in HSV-tk + Ganciclovir Gene Therapy for Prostate CancerMolecular Therapy, 2006
- Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate CancerEuropean Urology, 2005
- Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificityCancer Gene Therapy, 2005
- Virus-Directed Enzyme Prodrug Therapy: Intratumoral Administration of a Replication-Deficient Adenovirus Encoding Nitroreductase to Patients With Resectable Liver CancerJournal of Clinical Oncology, 2004
- Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate CancerClinical Cancer Research, 2004
- Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studiesSeminars in Oncology, 2001
- Combined Adenovirus-Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-Tolerated Therapy for Established Solid TumorsMolecular Therapy, 2001
- SUICIDE GENE THERAPY TOXICITY AFTER MULTIPLE AND REPEAT INJECTIONS IN PATIENTS WITH LOCALIZED PROSTATE CANCERJournal of Urology, 2000
- Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954Cancer Gene Therapy, 2000
- The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable MetaboliteHuman Gene Therapy, 1997